February 18, 2021 10:01 AM ESTUpdated 01:43 PM
Manufacturing

End­points Man­u­fac­tur­ing: Charles Riv­er makes a splash for cell and gene ther­a­py spe­cial­ist; 5 ques­tions with Ho­mol­o­gy Med­i­cines

Conner Mitchell

Af­ter a blis­ter­ing start to 2021, it seemed as though news in the biotech man­u­fac­tur­ing world had slowed to a more rea­son­able pace in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times